Gadolinium contrast agent associated stimulation of human fibroblast collagen production

Investigative Radiology

Volumn 46, Issue 11, 2011, Pages 711-717

  MacNeil, Sheila ^a   Bains, Sarah ^a   Johnson, Claire ^a   Idée, Jean Marc ^b   Factor, Cécile ^b   Jestin, Gaëlle ^b   Fretellier, Nathalie ^b   Morcos, Sameh K ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Laboratoire Guerbet   (France)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

collagen; fibroblasts; gadolinium contrast agents; nephrogenic systemic fibrosis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COLLAGEN; CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CELL STIMULATION; CELL VIABILITY; COLORIMETRY; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; MASS SPECTROMETRY; PRIORITY JOURNAL;

EID: 80053584426     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31822b1f38     Document Type: Article

References (30)

1. Cowper SE, Rabach M, Girardi M. Clinical and Histological Findings in Nephrogenic Systemic Fibrosis. Eur J Radiol. 2008;66:191-199.
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362. (Pubitemid 44300951)
3. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamiderelated nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22: 3174-3178. (Pubitemid 350202540)
4. Marckmann P, Skov L, Rossen K, et al. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol. 2008;9:161-168. (Pubitemid 351351062)
5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
6. Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol. 2006;61:905-906. (Pubitemid 44464118)
7. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
8. Port M, Idée JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
9. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
10. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76. (Pubitemid 46951248)
11. Morcos SK. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiol. 2011;21: 496-500.
12. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-512.
13. DaSilva M, Deming Mo, Fligiel SEG, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733-739.
14. Bhagavathula N, Dame MK, DaSilva M, et al. Fibroblast response to Gadolinium. Role for platelet derived growth factor receptor. Invest Radiol. 2010;45:1-9.
15. Fretellier N, Idée JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292-300.
16. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest Radiol. 2008;43:65-75.
17. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011;46:48-56.
18. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J. Pathol. 2008;214:584-593. (Pubitemid 351482273)
19. Varani J, Dasilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:1-8.
20. Edward M, Quinn JA, Burden AD, et al. Effect of difference classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology. 2010;256:735-743.
21. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
22. Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis. 2010;69:2017-2023.
23. Chakrabarty KH, Dawson RA, Harris P, et al. Development of autologous human dermal-epidermal composites based on sterilized human allodermis for clinical use. Br J Dermatol. 1999;141:811-823.
24. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;73:817-828.
25. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-2352. (Pubitemid 30498114)
26. Li JX, Liu JC, Wang K, et al. Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T cells. J Biol Inorg Chem. 2010;15:547-557.
27. Jenkins W, Perone P, Walker K, et al. Fibroblast response to lanthanoid metal ion stimulation: Potential contribution to fibrotic tissue injury. Biol Trace Elem Res. 2011 Apr 12. [Epub ahead of print.]
28. Laurent S, Vander Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137.
29. Idée JM, Port M, Dencausse A, et al. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am. 2009;47:855-869.
30. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991;9:409-415.